Key facts
- This page summarizes Eric Benevich's Form 4 filing for NEUROCRINE BIOSCIENCES INC (NBIX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jan 2023, 16:13.
Eric Benevich - 06 Jan 2023 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- NBIX
- Reported as of
- 06 Jan 2023
- Net transaction value
- -$50,000
- SEC form
- 4
- Accepted by SEC
- 10 Jan 2023, 16:13:51 UTC
- Prior SEC filing
- 01 Dec 2022
- Next SEC filing
- 02 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darin Lippoldt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Benevich filed Form 4 for NEUROCRINE BIOSCIENCES INC (NBIX) on 10 Jan 2023.
Change
- Previous filing in this sequence was filed on 01 Dec 2022.
- Current net transaction value: -$50,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBIX
transaction
Common Stock
Options Exercise
- Transaction value
- $17,296
- Shares
- +400
- Change %
- +2.6%
- Price
- $43.24
- Shares after
- 16,043
- Date
- 06 Jan 2023
- Ownership
- Direct
NBIX
transaction
Common Stock
Sale
- Transaction value
- $50,000
- Shares
- -400
- Change %
- -2.5%
- Price
- $125.00
- Shares after
- 15,643
- Date
- 06 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBIX
transaction
Derivative
Non-Qualified Stock Option
Options Exercise
- Transaction value
- $17,296
- Shares
- -400
- Change %
- -0.75%
- Price
- $43.24
- Shares after
- 53,143
- Date
- 06 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 400
- Exercise price
- $43.24
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Footnote F2
Option granted February 06, 2017 and vested monthly over four years.